呼吸 & 免疫学

澳门葡京赌博游戏的目标是改造呼吸系统 & 对患者的免疫护理, 从症状控制到疾病控制, 缓解与, one day, cure.


澳门葡京赌博游戏的承诺

有五十年的经验, 澳门葡京赌博游戏是呼吸护理领域的领导者,也是免疫学领域的颠覆者. We are committed to transforming care for some of the most debilitating and chronic respiratory and immune-mediated diseases. 澳门葡京赌博游戏的吸入和生物药物组合, 以及澳门葡京赌博游戏未来的管道, 寻求解决患者今天面临的挑战和大量未满足的医疗需求. 通过遵循科学, 澳门葡京赌博游戏专注于可持续地解决棘手和复杂的未解决问题. 澳门葡京赌博游戏的方法包括针对潜在的生物学, developing effective new drug modalities and combinations and applying a precision medicine approach from the start of discovering medicines, 一切都是在驾驶时提前发现的, 诊断与干预.



改变呼吸系统和免疫介导疾病患者的生活

Hear how we are addressing tough challenges to make a difference for patients – including advancing the science beyond just symptom control, 发现疾病的真正驱动因素, 使用新模式, 重新构想澳门葡京赌博游戏与合作伙伴的合作.







澳门葡京赌博游戏的重点领域

We are focused on chronic respiratory diseases including asthma and 慢性阻塞性肺疾病 (COPD), 以及免疫驱动的疾病,比如狼疮. 澳门葡京赌博游戏遵循科学来解决棘手和复杂的问题, unsolved problems - targeting the underlying biology and developing effective new drug modalities and combinations with the ultimate ambition of achieving disease modification and clinical remission.

点击以下链接,了解更多澳门葡京赌博游戏关注的领域:





澳门葡京赌博游戏的人民

We are an established leader in 呼吸 medicine and a disruptor in 免疫学 and we invest in and value our people. 澳门葡京赌博游戏的定位是在澳门葡京赌博游戏的研究中遵循科学, 同时也解决了呼吸和免疫介导疾病的治疗和管理问题. 澳门葡京赌博游戏的文化植根于诚信, 包容, 澳门葡京赌博游戏致力于加入和支持澳门葡京赌博游戏生活和工作的社区. 

呼吸 & 免疫学团队由:



在呼吸公司工作是一个激动人心的时刻 & 免疫学, as we continue to work towards transforming care for some of the most debilitating and chronic respiratory and immune-mediated diseases. By targeting the underlying biology and applying a precision medicine approach from the start of discovering medicines, 澳门葡京赌博游戏的目标是超越症状控制,改变疾病, 缓解和一天, cure.

玛丽亚Belvisi, 高级副总裁兼研究和早期开发主管,呼吸 & 免疫学,澳门葡京赌博游戏R&D、澳门葡京网赌游戏





加入澳门葡京赌博游戏的团队

澳门葡京赌博游戏的呼吸 & 免疫学 therapy area is driven by innovation and our commitment to make a real-life difference in patient’s lives. 这种差异从你开始. IDEA Pharma ranked us #1 on their Invention Index and #2 on their Innovation Index and we are recognised as a top employer in 2021/2022 by Forbes, 金融时报》 and Biospace. We need people like you who share our passion for science and determination to meet patients’ needs around the world.

Visit our 职业网站 and:








协作

Through collaboration and partnerships, we can accelerate positive change and outcomes for patients. 澳门葡京赌博游戏与领先的研究和学术机构合作, 公共卫生当局, 呼吸系统和免疫介导疾病的患者群体和专业组织.




澳门葡京赌博游戏的药品

澳门葡京赌博游戏无法在本网站上提供澳门葡京赌博游戏处方药的详细信息, 遵守规定.澳门葡京赌博游戏的药品 are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. 在某些情况下, healthcare professionals and patients can visit local AstraZeneca websites to find out more about our medicines. 请注意,在一些国家,澳门葡京赌博游戏不允许提供太多, 有时是任何, 关于澳门葡京赌博游戏处方药的信息,所以你应该寻找其他值得信赖的来源. 一定要向医疗保健专业人员咨询有关药物的建议.


accolit, accolit, Vanticon

扎鲁司

Bevespi大气层

格隆/ formoterol延胡索酸酯

Breztri大气层

布地奈德/格隆/ formoterol延胡索酸酯

Bricanyl Respules

特布他林

Bricanyl Turbuhaler

特布他林在干粉吸入器里

Daliresp / Daxas

roflumilast

Duaklir Genuair

aclidinium / formoterol

Eklira Genuair / Tudorza / Bretaris

aclidinium,一个LAMA

Fasenra

benralizumab

Oxis Turbuhaler

Oxis Turbuhaler

急性喘息性

布地奈德吸入混悬液

Pulmicort Turbuhaler

budesonide

Rhinocort

budesonide

Saphnelo

anifrolumab

Symbicort pMDI

布地奈德/ formoterol

Symbicort Turbuhaler

布地奈德/ formoterol

Tezspire

tezepelumab




R的管道&I

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

第三阶段/注册. refers to assets that are in Phase III or that have been submitted for regulatory approval and may include assets that are now launched in one or more major markets.


呼吸 & 免疫学(截至2023年11月9日)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

模块项目

模块项目







References

1. 联合国. 可持续发展目标. 可在:http://www.un.org/sustainabledevelopment/sustainable-development-goals/. [最后访问日期:2022年8月].

2. 世界卫生组织. 慢性阻塞性肺病字幕新闻. 可在:http://www.who.int /新闻/说明书/细节/慢性阻塞性肺疾病(copd). [最后访问日期:2022年8月].

3. Chen S, et al. 系统的临床文献综述, 人文主义的, 与GINA第4步或第5步治疗无法控制的哮喘相关的经济负担. 当前医学研究意见. 2018;34:2075–2088

4. 彼得斯SP, et al. 不受控制的哮喘:患病率、疾病负担和治疗选择的综述. Respir Med. 2006: 100 (7): 1139-51. 


Veeva ID: Z4-51416
筹备日期:2022年12月